Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice

Clinical and Experimental Rheumatology

Volumn 26, Issue 6, 2008, Pages 1059-1066

  Virkki, Liisa M ^a   Konttinen, Yrjö T ^a,b,c,d   Peltomaa, Ritva ^b   Suontama, Katariina ^b   Saario, Riicta ^e   Immonen, Kai ^f   Jäntti, Juha ^g   Tuomiranta, Tapani ^h   Nykänen, Pekka ⁱ   Hämeenkorpi, Risto ^j   Heikkilä, Sirpa ^k   Isomäki, Pia ^l   Nordström, Dan ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d COXA Hospital for Joint Replacement ^*  (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f Joensuu Central Hospital   (Finland)

^g Reumatism Foundation Hospital   (Finland)

^h Hatanpäänpuisto Hospital   (Finland)

ⁱ HYRT Rheumatology Clinic   (Finland)

^j Oulu Deaconesses' Institution   (Finland)

^k LAPLAND CENTRAL HOSPITAL   (Finland)

^l TAMPERE UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

Biologicals; Register; Retrospective observational study

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PODOPHYLLOTOXIN DERIVATIVE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; FINLAND; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REGISTER; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; FEMALE; FINLAND; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59149097206     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. WOLFE F, MICHAUD K, PINCUS T: Do rheumatology cost-effectiveness analyses make sense? Rheumatology 2004a; 43: 4-6.
2. WOLFE F, MICHAUD K, DEWITT EM: Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis 2004b; 63 (Suppl. 2): Ii13-ii17.
3. ZINK A, STRANGFELD A, SCHNEIDER M et al.: Listing J: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54: 3399-407.
4. REVICKI DA, FRANK L: Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423-34.
5. NORDSTROM DC, KONTTINEN L, KORPELA M et al.: Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 2006; 26: 741-8.
6. KONTTINEN L, HONKANEN V, UOTILA T et al.: ROB-FIN study group: Biological treatment in rheumatic diseases: Results from a longitudinal surveillance: Adverse events. Rheumatol Int 2006a; 26: 916-22.
7. KONTTINEN L, KANKAANPAA E, LUOSUJARVI R et al.: ROB-FIN Study Group: Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: An observational study. Clin Rheumatol 2006b; 25: 882-4.
8. KONTTINEN L, TUOMPO R, UUSITALO T et al.: ROB-FIN Study Group: Anti-TNF therapy in the treatment of ankylosing spondylitis: The Finnish experience. Clin Rheumatol 2007; 26: 1693-700.
9. WONG JB: Cost-effectiveness of anti-tumor necrosis factor agents: Clin Exp Rheumatol 2004; 22 (Suppl. 35): S65-70.
10. BANSBACK NJ, REGIER DA, ARA R et al.: An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-alpha antagonists. Drugs 2005; 65: 473-96.
11. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
12. KOBELT G, LINDGREN P, SINGH A, KLARESKOG L: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005; 64: 1174-9.
13. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
14. SCOTT DL, PUGNER K, KAARELA K, DOYLE DV, WOOLF A, HOLMES J, HIEKE K: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000; 39: 122-32.
15. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
16. VAN DER HEIJDE DM, VAN LEEUWEN MA, VAN RIEL PL, VAN DE PUTTE LB: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792-6.
17. CHOI HK, SEEGER JD, KUNTZ KM: A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 2316-27.
18. WONG JB, SINGH G, KAVANAUGH A: Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113: 400-8.
19. KOBELT G, JONSSON L, YOUNG A, EBERHARDT K: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003; 42: 326-35.
20. BRENNAN A, BANSBACK N, REYNOLDS A, CONWAY P: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004; 43: 62-72.
21. KOBELT G, EBERHARDT K, GEBOREK P: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4-10.
22. WELSING PM, SEVERENS JL, HARTMAN M, VAN RIEL PL, LAAN RF: Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004; 51: 964-73.
23. BRENNAN A, BANSBACK N, NIXON R et al.: Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007; 46: 1345-54.
24. WAILOO AJ, BANSBACK N, BRENNAN A, MICHAUD K, NIXON RM, WOLFE F: Biologic drugs for rheumatoid arthritis in the Medicare program: A cost-effectiveness analysis. Arthritis Rheum 2008; 58: 939-46.
25. RAWLINS MD, CULYER AJ: National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224-7.
26. MAETZEL A: Cost-effectiOeness analysis: out of touch with clinical reality? Arthritis Rheum 2005; 53: 3-4.
27. McGREGORUM: Cost-utility analysis: use QALYs only with great caution. CMAJ 2003; 168: 433-4.
28. BERESNIAK A, RUSSELL AS, HARAOUI B, BESSETTE L, BOMBARDIER C, DURU G: Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007; 34: 2193-200.
29. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003; 1: 20.